Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.71-0.19 (-1.47%)
At close: 04:00PM EST
12.71 0.00 (0.00%)
After hours: 04:31PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close12.90
Open12.72
Bid7.60 x 800
Ask16.29 x 1100
Day's Range12.69 - 13.41
52 Week Range12.69 - 36.48
Volume406,081
Avg. Volume470,267
Market Cap778.589M
Beta (5Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MGNX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MacroGenics, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/24/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, Nov. 03, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following conferences in November and December 2021: Credit Suisse 30th Annual Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview

  • GlobeNewswire

    MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results

    Investigational New Drug (IND) application submitted for MGD024, a next generation DART® molecule targeting CD123 and CD3 for AMLU.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP manufacturing facility to produce MARGENZA® drug substance Discontinuing enrollment of Cohort A of Phase 2/3 MAHOGANY study of margetuximab Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company fo

  • GlobeNewswire

    MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call

    ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2021 after the market closes on Tuesday, November 2, 2021. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, N

Advertisement
Advertisement